Washington, D.C.-based Bernstein Cos. filed a commencement notice April 28 for the residential conversion of the Hooper Building at 141 W. Fourth St. The city of Cincinnati Department of Building ...

Conversion therapy might harm a young person's long-term heart health, a new study says. Young adults assigned male at birth were nearly three times as likely to be diagnosed with high blood ...

Customers at CVS will be able to buy weight loss drug Wegovy at a discount. Cash purchasers can get the Novo Nordisk–made product for $499 per month. The pharma company has also recently struck ...

A Complete Unknown tops this week’s Official Film Chart for the first time. The James Mangold-directed Bob Dylan biopic, starring Timothée Chalamet as a young Dylan, lifts five to the summit ...

COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month ...

Novo Nordisk works with Hims & Hers, Ro, LifeMD to expand Wegovy access Hims & Hers, LifeMD shares jump more than 25% and 36% respectively Danish drugmaker says move is "very clear message" Wegovy ...

CVS’ pharmacy benefit manager Caremark also reached an agreement with Danish drugmaker Novo Nordisk to give its weight loss drug Wegovy preferred access on Caremark’s standard formulary ...

Lilly's Zepbound overtook Novo's Wegovy as the leading obesity drug, according to the latest prescription data last month. But Novo CEO Lars Jørgensen attributes the softness in sales to the ...

CVS Health on Thursday said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Stream San Diego News ...

Below, we discuss nine important factors to keep in mind when deciding to do a Roth conversion. When you convert a traditional IRA to a Roth IRA, you will have to pay income tax on the conversion ...

Wegovy sales expected to recover after FDA ban on copycats Guidance for 2025 sales, profit both cut Slower US obesity market penetration Q4 sales narrowly miss, profits beat Shares up 3.4% ...